Former FDA Commissioner Scott Gottlieb, biosimilars manufacturers and industry consultants pushed back Monday against a proposal to scrap the U.S. biosimilars pathway and instead impose price controls on off-patent biologics.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,